20 - World Journal of Gastroenterology

Miranda M, Marí M, Ardite E, Morales A. GSH transport in
mitochondria: defense against TNF-induced oxidative stress
and alcohol-induced defect. Am J Physiol 1997; 273: G7-G17
14 Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O.
Pentoxifylline improves short-term survival in severe acute
alcoholic hepatitis: a double-blind, placebo-controlled trial.
Gastroenterology 2000; 119: 1637-1648
15 Naveau S, Chollet-Martin S, Dharancy S, Mathurin P, Jouet P,
Piquet MA, Davion T, Oberti F, Broët P, Emilie D. A doubleblind
randomized controlled trial of infliximab associated
with prednisolone in acute alcoholic hepatitis. Hepatology
2004; 39: 1390-1397
16 Boetticher NC, Peine CJ, Kwo P, Abrams GA, Patel T, Aqel
B, Boardman L, Gores GJ, Harmsen WS, McClain CJ, Kamath
PS, Shah VH. A randomized, double-blinded, placebocontrolled
multicenter trial of etanercept in the treatment of
alcoholic hepatitis. Gastroenterology 2008; 135: 1953-1960
17 Mezey E, Potter JJ, Rennie-Tankersley L, Caballeria J, Pares
A. A randomized placebo controlled trial of vitamin E for
alcoholic hepatitis. J Hepatol 2004; 40: 40-46
18 Stewart S, Prince M, Bassendine M, Hudson M, James O,
Jones D, Record C, Day CP. A randomized trial of antioxidant
therapy alone or with corticosteroids in acute alcoholic
hepatitis. J Hepatol 2007; 47: 277-283
19 Wright C, Moore RD. Disulfiram treatment of alcoholism.
Am J Med 1990; 88: 647-655
20 Cvek B, Dvorak Z. The value of proteasome inhibition in
cancer. Can the old drug, disulfiram, have a bright new
future as a novel proteasome inhibitor? Drug Discov Today
2008; 13: 716-722
21 Wickström M, Danielsson K, Rickardson L, Gullbo J, Nygren
P, Isaksson A, Larsson R, Lövborg H. Pharmacological profiling
of disulfiram using human tumor cell lines and human
tumor cells from patients. Biochem Pharmacol 2007; 73: 25-33
22 Naujokat C, Berges C, Höh A, Wieczorek H, Fuchs D, Ovens
J, Miltz M, Sadeghi M, Opelz G, Daniel V. Proteasomal
chymotrypsin-like peptidase activity is required for essential
functions of human monocyte-derived dendritic cells. Immunology
2007; 120: 120-132
23 Kloetzel PM. The proteasome and MHC class I antigen processing.
Biochim Biophys Acta 2004; 1695: 225-233
24 Visekruna A, Joeris T, Seidel D, Kroesen A, Loddenkemper
C, Zeitz M, Kaufmann SH, Schmidt-Ullrich R, Steinhoff U.
Proteasome-mediated degradation of IkappaBalpha and
processing of p105 in Crohn disease and ulcerative colitis. J
Clin Invest 2006; 116: 3195-3203
25 Groll M, Huber R, Moroder L. The persisting challenge of
selective and specific proteasome inhibition. J Pept Sci 2009;
15: 58-66
26 Gilardini A, Marmiroli P, Cavaletti G. Proteasome inhibition:
a promising strategy for treating cancer, but what about
neurotoxicity? Curr Med Chem 2008; 15: 3025-3035
27 Chauhan D, Bianchi G, Anderson KC. Targeting the UPS as
therapy in multiple myeloma. BMC Biochem 2008; 9 Suppl 1:
S1
28 Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath
S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian
R, Siegel D, Orlowski RZ, Kuter D, Limentani SA,
Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J,
Schenkein DP, Anderson KC. A phase 2 study of bortezomib
in relapsed, refractory myeloma. N Engl J Med 2003; 348:
2609-2617
29 Dou QP, Goldfarb RH. Bortezomib (millennium pharmaceuticals).
IDrugs 2002; 5: 828-834
30 Davis NB, Taber DA, Ansari RH, Ryan CW, George C,
Vokes EE, Vogelzang NJ, Stadler WM. Phase II trial of PS-341
in patients with renal cell cancer: a University of Chicago
phase II consortium study. J Clin Oncol 2004; 22: 115-119
31 Kondagunta GV, Drucker B, Schwartz L, Bacik J, Marion S,
WJG|www.wjgnet.com
Bardag-Gorce F. Proteasome inhibitor and oxidative stress
Russo P, Mazumdar M, Motzer RJ. Phase II trial of bortezomib
for patients with advanced renal cell carcinoma. J Clin
Oncol 2004; 22: 3720-3725
32 Shah MH, Young D, Kindler HL, Webb I, Kleiber B, Wright
J, Grever M. Phase II study of the proteasome inhibitor bortezomib
(PS-341) in patients with metastatic neuroendocrine
tumors. Clin Cancer Res 2004; 10: 6111-6118
33 Papandreou CN, Daliani DD, Nix D, Yang H, Madden T,
Wang X, Pien CS, Millikan RE, Tu SM, Pagliaro L, Kim J, Adams
J, Elliott P, Esseltine D, Petrusich A, Dieringer P, Perez
C, Logothetis CJ. Phase I trial of the proteasome inhibitor
bortezomib in patients with advanced solid tumors with observations
in androgen-independent prostate cancer. J Clin
Oncol 2004; 22: 2108-2121
34 Jung T, Engels M, Kaiser B, Poppek D, Grune T. Intracellular
distribution of oxidized proteins and proteasome in HT22
cells during oxidative stress. Free Radic Biol Med 2006; 40:
1303-1312
35 Kelly SM, Vanslyke JK, Musil LS. Regulation of ubiquitinproteasome
system mediated degradation by cytosolic stress.
Mol Biol Cell 2007; 18: 4279-4291
36 Yamamoto N, Sawada H, Izumi Y, Kume T, Katsuki H,
Shimohama S, Akaike A. Proteasome inhibition induces
glutathione synthesis and protects cells from oxidative
stress: relevance to Parkinson disease. J Biol Chem 2007; 282:
4364-4372
37 Williams AJ, Dave JR, Tortella FC. Neuroprotection with the
proteasome inhibitor MLN519 in focal ischemic brain injury:
relation to nuclear factor kappaB (NF-kappaB), inflammatory
gene expression, and leukocyte infiltration. Neurochem
Int 2006; 49: 106-112
38 Nencioni A, Grünebach F, Patrone F, Ballestrero A, Brossart
P. Proteasome inhibitors: antitumor effects and beyond. Leukemia
2007; 21: 30-36
39 Lorenz M, Wilck N, Meiners S, Ludwig A, Baumann G,
Stangl K, Stangl V. Proteasome inhibition prevents experimentally-induced
endothelial dysfunction. Life Sci 2009; 84:
929-934
40 Donohue TM, Cederbaum AI, French SW, Barve S, Gao B,
Osna NA. Role of the proteasome in ethanol-induced liver
pathology. Alcohol Clin Exp Res 2007; 31: 1446-1459
41 French SW. Intragastric ethanol infusion model for cellular
and molecular studies of alcoholic liver disease. J Biomed Sci
2001; 8: 20-27
42 Preedy VR, Adachi J, Asano M, Koll M, Mantle D, Niemela O,
Parkkila S, Paice AG, Peters T, Rajendram R, Seitz H, Ueno
Y, Worrall S. Free radicals in alcoholic myopathy: indices of
damage and preventive studies. Free Radic Biol Med 2002; 32:
683-687
43 Gouillon Z, Lucas D, Li J, Hagbjork AL, French BA, Fu P,
Fang C, Ingelman-Sundberg M, Donohue TM, French SW.
Inhibition of ethanol-induced liver disease in the intragastric
feeding rat model by chlormethiazole. Proc Soc Exp Biol Med
2000; 224: 302-308
44 Bousquet-Dubouch MP, Nguen S, Bouyssié D, Burlet-
Schiltz O, French SW, Monsarrat B, Bardag-Gorce F. Chronic
ethanol feeding affects proteasome-interacting proteins. Proteomics
2009; 9: 3609-3622
45 Oliva J, Dedes J, Li J, French SW, Bardag-Gorce F. Epigenetics
of proteasome inhibition in the liver of rats fed ethanol
chronically. World J Gastroenterol 2009; 15: 705-712
46 Zeng T, Zhang CL, Zhu ZP, Yu LH, Zhao XL, Xie KQ. Diallyl
trisulfide (DATS) effectively attenuated oxidative stressmediated
liver injury and hepatic mitochondrial dysfunction
in acute ethanol-exposed mice. Toxicology 2008; 252: 86-91
47 Das SK, Vasudevan DM. Alcohol-induced oxidative stress.
Life Sci 2007; 81: 177-187
48 Bardag-Gorce F, Oliva J, Lin A, Li J, French BA, French SW.
Proteasome inhibitor up regulates liver antioxidative en-
2561 May 28, 2011|Volume 17|Issue 20|